Results: 4

1.
Fig. 1

Fig. 1. From: Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies.

Induction regimen of antiangiogenic and antitumor immunity agents administered in an 8-week series. The dashed lines indicate the targeted mechanism proposed

Eduardo Lasalvia-Prisco, et al. Med Oncol. 2012 December;29(5):3626-3633.
2.
Fig. 2

Fig. 2. From: Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies.

The Kaplan–Meier survival curves plotted for patients with pancreatic cancer, NSCLC, and prostate cancer with poor prognoses. G1 groups of patients treated with standard chemotherapy; G2 groups of patients treated with standard chemotherapy and an induction regimen of antiangiogenic and antitumor immunity agents. Mean survival is significantly longer for G2 than for G1 for patients with the three primary malignancies analyzed: 18.0 versus 10.2 months (log-rank, p = 0.036), 16.7 versus 12.1 months (log-rank, p = 0.042), and 20.4 versus 16.8 months (log-rank, p = 0.048) for pancreatic cancer, NSCLC, and prostate cancer, respectively

Eduardo Lasalvia-Prisco, et al. Med Oncol. 2012 December;29(5):3626-3633.
3.
Fig. 3

Fig. 3. From: Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies.

Percentage of baseline (pretreatment) values (mean ± SD) at 3 months of follow-up in the 90G1 cohort treated with standard chemotherapy compared with the 90G2 cohort treated with the same chemotherapy and an induction regimen of antiangiogenic and antitumor immunity agents. Antiangiogenesis was monitored by measuring VEGF and angiostatin blood levels. Antitumor immunity conditioning was determining by assessing the number and presence of T-Regs and aDCs. Antitumor immunity was tested with DTH and IFN-ELISPot assays challenged with an autologous hemoderivative containing tumor antigens

Eduardo Lasalvia-Prisco, et al. Med Oncol. 2012 December;29(5):3626-3633.
4.
Fig. 4

Fig. 4. From: Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies.

The safety and toxicity profiles of the 90G2 cohort treated with the induction regimen of antiangiogenic and antitumor immunity agents in combination with chemotherapy and the 90G1 cohort treated with standard chemotherapy alone were not statistically different in the 2-year follow-up period (p > 0.05). Toxicities were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v3.0 of the National Cancer Institute. Quality of life was scored using the current core questionnaire of the EORTC QLQ-C30

Eduardo Lasalvia-Prisco, et al. Med Oncol. 2012 December;29(5):3626-3633.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk